By Fineline Cube 
China-based Akeso Biopharma (HKG: 9926) announced the initiation of a Phase Ia clinical study for its internally developed Trop2/Nectin4 bispecific antibody-drug conjugate (ADC) AK146D1, with the first patient already dosed. The drug is being evaluated for the treatment of advanced solid tumors.
Preclinical Results and Therapeutic Potential
Preclinical studies demonstrated that AK146D1 exhibited potent antitumor activity and a favorable safety profile in tumors expressing Trop2 or Nectin4. These results highlight the drug’s significant therapeutic potential for patients with advanced solid tumors.
Regulatory Approvals
To date, AK146D1 has received clinical trial approvals from multiple regulatory agencies, including the U.S. FDA, Australia’s TGA, and China’s NMPA.-Fineline Info & Tech